Apremilast in the Treatment of Plaque Psoriasis: Differential Use in Psoriasis

References

• Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol. 2012;83(12):1583–1590. doi:10.1016/j.bcp.2012.01.001
   PubMed Web of Science ®Google Scholar
• Otezla [Full Prescribing Information]. Celgene Corporation, Summit, NJ. Available from: https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf. Accessed November 10, 2021.
   Google Scholar
• Deeks ED. Apremilast: a Review in Psoriasis and Psoriatic Arthritis. Drugs. 2015;75(12):1393–1403. doi:10.1007/s40265-015-0439-1
   PubMed Web of Science ®Google Scholar
• Papp K, Reich K, Leonardi CL, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a Phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015;73(1):37–49. doi:10.1016/j.jaad.2015.03.049
   PubMed Web of Science ®Google Scholar
• Paul C, Cather J, Gooderham M, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2). Br J Dermatol. 2015;173(6):1387–1399. doi:10.1111/bjd.14164
   PubMed Web of Science ®Google Scholar
• Reich K, Gooderham M, Green L, et al. The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE). J Eur Acad Dermatol Venereol. 2017;31(3):507–517. doi:10.1111/jdv.14015
   PubMed Web of Science ®Google Scholar
• Van Voorhees AS, Stein Gold L, Lebwohl M, et al. Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study. J Am Acad Dermatol. 2020;83(1):96–103. doi:10.1016/j.jaad.2020.01.072
   PubMed Web of Science ®Google Scholar
• Crowley J, Thaçi D, Joly P, et al. Long-term safety and tolerability of apremilast in patients with psoriasis: pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2). J Am Acad Dermatol. 2017;77(2):310–317.e311. doi:10.1016/j.jaad.2017.01.052
   PubMed Web of Science ®Google Scholar
• Lanna C, Cesaroni GM, Mazzilli S, et al. Apremilast as a target therapy for nail psoriasis: a real-life observational study proving its efficacy in restoring the nail unit. J Dermatolog Treat;2020. 1–5. doi:10.1080/09546634.2020.1801976
   Web of Science ®Google Scholar
• Muñoz-Santos C, Sola-Ortigosa J, Vidal D, Guilabert A. Apremilast improves quality of life and ultrasonography parameters in patients with nail psoriasis: a prospective cohort study. J Dermatol. 2021;48(10):1593–1596. doi:10.1111/1346-8138.16074
   PubMed Web of Science ®Google Scholar
• Oak ASW, Ho-Pham H, Elewski BE. Improvement of 11 patients with nail psoriasis with apremilast: results of an investigator-initiated open-label study. J Am Acad Dermatol. 2020;83(6):1830–1832. doi:10.1016/j.jaad.2020.05.087
   PubMed Web of Science ®Google Scholar
• Bissonnette R, Pariser DM, Wasel NR, et al. Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: results of a pooled analysis from Phase II PSOR-005 and Phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis. J Am Acad Dermatol. 2016;75(1):99–105. doi:10.1016/j.jaad.2016.02.1164
   PubMed Web of Science ®Google Scholar
• Ständer S, Syring F, Ludwig RJ, Thaçi D. Successful Treatment of Refractory Palmoplantar Pustular Psoriasis With Apremilast: a Case Series. Front Med. 2020;7:543944. doi:10.3389/fmed.2020.543944
   PubMed Web of Science ®Google Scholar
• Thaçi D, Kimball A, Foley P, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient-reported outcomes in the treatment of moderate to severe psoriasis: results of two phase III randomized, controlled trials. J Eur Acad Dermatol Venereol. 2017;31(3):498–506. doi:10.1111/jdv.13918
   PubMed Web of Science ®Google Scholar
• Strober B, Bagel J, Lebwohl M, et al. Efficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis With Lower BSA: week 16 Results from the UNVEIL Study. J Drugs Dermatol. 2017;16(8):801–808.
   PubMed Web of Science ®Google Scholar
• Zhang R, Maratos-Flier E, Flier JS. Reduced adiposity and high-fat diet-induced adipose inflammation in mice deficient for phosphodiesterase 4B. Endocrinology. 2009;150(7):3076–3082. doi:10.1210/en.2009-0108
   PubMed Web of Science ®Google Scholar
• Hagberg KW, Persson R, Vasilakis-Scaramozza C, et al. Herpes Zoster, Hepatitis C, and Tuberculosis Risk with Apremilast Compared to Biologics, DMARDs and Corticosteroids to Treat Psoriasis and Psoriatic Arthritis. Clin Epidemiol. 2020;12:153–161. doi:10.2147/CLEP.S239511
   PubMed Web of Science ®Google Scholar
• Balogh EA, Bashyam AM, Ghamrawi RI, Feldman SR. Emerging systemic drugs in the treatment of plaque psoriasis. Expert Opin Emerg Drugs. 2020;25(2):89–100. doi:10.1080/14728214.2020.1745773
   PubMed Web of Science ®Google Scholar
• How much does Otezla® (APREMILAST) cost?: official Website. Otezla® (apremilast) - Official Website. Availablr from: https://www.otezla.com/plaque-psoriasis-treatment/how-much-does-otezla-cost. Accessed November 21, 2021.
   Google Scholar
• Paying for ENBREL: the cost of ENBREL and financial support options. Enbrel® (etanercept). Availablr from: https://www.enbrel.com/financial-support. Accessed November 21, 2021.
   Google Scholar
• Tanaka M, Ozeki Y, Matsuyama F, Murata T, Imafuku S, Nakamura T. Apremilast Prolongs the Time to First Biologic Therapy in Japanese Patients with Psoriasis. Dermatol Ther (Heidelb). 2021;12:451–466. doi:10.1007/s13555-021-00659-w
   PubMed Web of Science ®Google Scholar
• Kromer C, Celis D, Sonntag D, Peitsch WK. Biologicals and small molecules in psoriasis: a systematic review of economic evaluations. PLoS One. 2018;13(1):e0189765. doi:10.1371/journal.pone.0189765
   PubMed Web of Science ®Google Scholar